Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study (PROMICRO-3)
Coronary Artery Disease
About this trial
This is an interventional other trial for Coronary Artery Disease focused on measuring Coronary Flow, Coronary Resistances, Platelet Reactivity
Eligibility Criteria
Inclusion Criteria: Paitents with stable CAD referred to elective percutaneous coronary intervention (PCI) of an isolated, functionally significant (as confirmed by a fractional flow reserve [FFR] <0.80) stenosis located in the proximal two-thirds of a major coronary artery Exclusion Criteria: age <18 years or ≥75 years, body weight <60 kg, previous transient ischemic attack (TIA) or stroke, acute coronary syndromes, administration of glycoprotein IIb/IIIa inhibitors, platelet count <70x109/l, high bleeding risk (active internal bleeding, history of haemorrhagic stroke, intracranial neoplasm, arteriovenous malformation or aneurysm, ischemic stroke in the previous 3 months), coronary bypass graft surgery in the previous 3 months, severe chronic renal failure (serum creatinine ≥2 mg/dl), previous myocardial infarction, left ventricular ejection fraction less than 50%, left ventricle wall-motion abnormalities, left ventricular hypertrophy, chronic total occlusion, lesions with extensive calcifications requiring rotational atherectomy, in-stent restenosis, bifurcation lesions with side branch diameter of more than 2 mm, ostial lesion, and contraindications to adenosine
Sites / Locations
- Aalst cardiovascular center
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Prasugrel Group
Ticagrelor
Patient treated with 60 mg prasugrel 12 hours before the procedure
Patient treated with 180 mg ticagrelor 12 hours before the procedure